Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Fluorodeoxyglucose F18
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Prednisone
/ therapeutic use
Prognosis
Progression-Free Survival
Vincristine
/ therapeutic use
DLBCL
FDG
FLT
PET/CT
PFS
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
01
01
2021
accepted:
04
04
2021
pubmed:
29
4
2021
medline:
24
7
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
To determine whether interim 3'-deoxy-3'-[ Ninety-two prospectively enrolled patients with DLBCL underwent both FLT-PET/CT and FDG-PET/CT 18-24 days after two cycles of R-CHOP/R-EPOCH. Deauville-criteria, PERCIST1.0, standardized uptake value (SUV), total lesion glycolysis (TLG), and metabolic tumor volume were used to interpret iFDG-PET/CT while dichotomous visual interpretation was used to interpret iFLT-PET/CT and the results were compared with the 3- and 5-year PFS. iFLT-PET/CT was negative in 67 (73%) and positive in 25 (27%) patients. iFDG-PET/CT by Deauville criteria was negative (Deauville scores [DS] of 1-3) in 53 (58%) and positive (DS = 4-5) in 39 (42%) patients. Of the 67 iFLT-PET/CT-negative patients, 7 (10.4%) progressed at a median of 14.1 months whereas 14/25 (56.0%) iFLT-PET/CT-positive patients progressed at a median of 7.8 months (P < .0001). Of the 53 Deauville-negative patients, 9 (17.0%) progressed at a median of 14.1 months whereas 12/39 (30.8%) Deauville-positive patients progressed at a median of 5.6 months (P = .11). In multivariate analysis, including iFLT-PET/CT, PERCIST, interim TLG, and interim SUV In patients with DLBCL given R-CHOP/R-EPOCH, iFLT-PET/CT is a superior independent predictor of outcome compared with iFDG-PET/CT.
Identifiants
pubmed: 33909086
doi: 10.1007/s00259-021-05353-9
pii: 10.1007/s00259-021-05353-9
pmc: PMC8263539
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2883-2893Subventions
Organisme : NCI NIH HHS
ID : R01 CA152923
Pays : United States
Références
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
doi: 10.1200/JCO.2006.09.2403
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.
doi: 10.1200/JCO.2006.08.2305
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.
doi: 10.1200/JCO.2013.54.8800
Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.
doi: 10.1182/blood-2005-01-0272
Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.
doi: 10.1200/JCO.2009.26.5942
Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.
doi: 10.1182/blood-2010-12-327767
Thomas A, Gingrich RD, Smith BJ, Jacobus L, Ristow K, Allmer C, et al. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ‘indeterminate’ reports. Leuk Lymph. 2010;51:439–46.
doi: 10.3109/10428190903560198
Cheson BD, Kostakoglu L. FDG-PET for early response assessment in lymphomas: part 2—diffuse large B-cell lymphoma. Use of Quantitative PET Evaluation Oncology (Williston Park). 2017;31:71–6.
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1356–63.
doi: 10.1093/annonc/mdf256
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.
pubmed: 12163626
Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.
doi: 10.2967/jnumed.107.042093
Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.
doi: 10.2967/jnumed.108.057703
Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386–92.
doi: 10.2967/jnumed.110.082586
Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–7.
doi: 10.1093/annonc/mdn671
Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al. Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064–71.
doi: 10.1007/s00259-011-1741-0
Le Gouill S, Casasnovas RO. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017;129:3059–70.
doi: 10.1182/blood-2016-05-672196
Burggraaff CN, de Jong A, Hoekstra OS, Hoetjes NJ, Nievelstein RAJ, Jansma EP, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:65–79.
doi: 10.1007/s00259-018-4103-3
Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110.
doi: 10.1007/s00259-017-3690-8
Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction. Eur J Nucl Med Mol Imaging. 2003;30:682–8.
doi: 10.1007/s00259-003-1120-6
Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymph. 2009;50:1257–60.
doi: 10.1080/10428190903040048
Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–61.
doi: 10.1158/0008-5472.CAN-06-1955
Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim 18F-FLT PET/CT versus 18F-FDG PET/CT using IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring of diffuse large B-cell lymphoma. Radiology. 2016;280:220–9.
doi: 10.1148/radiol.2015150689
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.
doi: 10.2967/jnumed.108.057307
Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82:1164–71.
doi: 10.1016/j.ijrobp.2010.12.055
Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020;135:2224–34. https://doi.org/10.1182/blood.2019003277 .
doi: 10.1182/blood.2019003277
pubmed: 32232481
pmcid: 7316220
Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16875 .
Davies L, Jenkins S, Allen J. Taylor PR. Tissue-resident macrophages Nat Immunol. 2013;14:986–95.
doi: 10.1038/ni.2705
Davies LC, Rosas M, Jenkins SJ, Liao CT, Scurr MJ, Brombacher F, et al. Distinct bone marrow-derived and tissue resident macrophage-lineages proliferate at key stages during inflammation. Nat Commun. 2013;4:1886.
doi: 10.1038/ncomms2877
Post GR, Yuan Y, Holthoff ER, Quick CM, Post SR. Identification of a novel monocytic phenotype in classic Hodgkin lymphoma tumor microenvironment. PLoS One. 2019;14:e0224621. https://doi.org/10.1371/journal.pone.0224621 .
doi: 10.1371/journal.pone.0224621
pubmed: 31714922
pmcid: 6850552
Cioroianu AL, Stinga PI, Striclaru L, Cioplea MD, Nichita L, Popp C, et al. Tumor Microenvironment in diffuse large B-cell lymphoma: role and prognosis. Anal Cell Pathol (Amst). 2019;2019:8586354.
Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, et al. Prospective study of 3'-deoxy-3'-18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57:728–34.
doi: 10.2967/jnumed.115.166769
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol. 2019;37:1790–9.
doi: 10.1200/JCO.18.01994
Lee SJ, Oh SJ, Chi DY, Kil HS, Kim EN, Ryu JS, et al. Simple and highly efficient synthesis of 3′-deoxy-3′-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging. 2007. https://doi.org/10.1007/s00259-007-0391-8 .